

PRESS RELEASE 29.07.2025

CGenetix Secures Exclusive Licenses for Cutting-Edge Epigenetic Biomarkers in Kidney Transplantation

Paris, France – 29-07-2025 – CGenetix, a pioneering biotechnology company focused on molecular precision diagnostics in transplantation medicine, today announces the acquisition of two exclusive patent licenses that significantly strengthen its position in the field of epigenetic biomarker discovery for kidney transplantation.

The company has secured :

- An **exclusive license from Yissum**, the technology transfer company of the Hebrew University of Jerusalem, for 5 patents' families covering innovative technologies that enhance the detection of epigenetic molecular markers, specifically tailored for applications in kidney transplant monitoring.
- An **exclusive license for a co-owned patent** developed in collaboration with **Inserm Transfert, Assistance Publique–Hôpitaux de Paris (AP-HP), Université Paris Cité, Sorbonne Université & CNRS**, protecting a **first-generation panel of blood and urine-based epigenetic biomarkers** targeting kidney-specific cell populations, with strong potential to transform non-invasive monitoring of transplant patients.

“These two strategic licenses position us at the forefront of molecular diagnostics in the transplantation field,” said Geoffroy POULET, CEO. “By combining academic excellence from world-renowned institutions with our translational development capabilities, we aim to accelerate the clinical adoption of robust, non-invasive tools that will ultimately improve kidney graft survival and patient outcomes.”

This dual acquisition further cements CGenetix’s commitment to build a proprietary pipeline of next-generation diagnostic solutions based on precision epigenetics, with a focus on organ-specific health monitoring.

Media Contact

Geoffroy POULET

CEO

Geoffroy.poulet@cgenetix.com

www.cgenetix.com